A novel mechanism to correct calcium channel dysfunction
Targeting RyR
Targeting a fundamental signaling pathway
Decades of foundational research have made it possible to drug ryanodine receptors (RyRs), ion channels that regulate the intracellular flow of calcium in nearly all cell types and are essential for muscle contraction.
We are developing a novel class of therapeutics, called Rycals®, for serious diseases with high unmet need in which ryanodine receptors play a critical role in disease progression.

Breaking the
cycle of heart failure
Heart failure is a chronic, progressive condition with current treatments aiming to slow decline in cardiac function and manage symptoms. Our lead candidate, ARM210, has the potential to break the cycle of heart failure by addressing an underlying driver of disease progression and by strengthening both cardiac and skeletal muscle cells.